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The macrophage infectivity potentiator protein from Trypano-
soma cruzi (TcMIP) is a major virulence factor secreted by the
etiological agent of Chagas’ disease. It is functionally involved
in host cell invasion. We have determined the three-dimen-
sional crystal structure of TcMIP at 1.7 Å resolution. The mono-
meric protein displays a peptidyl-prolyl cis–trans isomerase
(PPIase) core, encompassing the characteristic rotamase
hydrophobic active site, thus explaining the strong inhibition
of TcMIP by the immunosuppressant FK506 and related drugs.
In TcMIP, the twisted β-sheet of the core is extended by an
extra β-strand, preceded by a long, exposed N-terminal α-helix,
which might be a target recognition element. An invasion assay
shows that the MIP protein from Legionella pneumophila
(LpMIP), which has an equivalent N-terminal α-helix, can
substitute for TcMIP. An additional exposed α-helix, this one
unique to TcMIP, is located in the C-terminus of the protein.
The high-resolution structure reported here opens the possi-
bility for the design of new inhibitory drugs that might be
useful for the clinical treatment of American trypanosomiasis.
INTRODUCTION
Chagas’ disease or American trypanosomiasis is a severe sick-
ness that afflicts 16–18 million people in Central and South
America. According to the World Health Organization, it is
endemic in 21 countries, where ∼100 million people are at risk.
Chagas’ disease is caused by the flagellated protozoan Trypano-
soma cruzi, a parasite able to evade the host immune system.
The lack of a vaccine and the fact that existing drugs are only
partially effective make American trypanosomiasis an essentially
incurable disease.
Trypomastigotes are the non-dividing infective forms of the
parasite, which penetrate a wide range of phagocytic and non-
phagocytic mammalian cells. Invasion of the host cell involves
the activation of signal transduction pathways through a series of
complex steps, which are not fully understood (Burleigh and
Andrews, 1998).
Trypanosoma cruzi macrophage infectivity potentiator
(TcMIP) is a peptidyl-prolyl cis–trans isomerase (PPIase) secreted
by T. cruzi trypomastigotes (Moro et al., 1995). MIP proteins
have also been reported as virulence factors in the pathogenic
intracellular bacteria Legionella pneumophila (Engleberg et al.,
1989) and Chlamydia trachomatis (Lundemose et al., 1991), the
etiological agents of human Legionnaires’ disease and chlamyd-
iasis, respectively. These PPIases are inhibited by the immuno-
suppressant macrolide antibiotic FK506, and are thus related
to the FK506 binding proteins (FKBPs). In Saccharomyces
cerevisiae, these proteins mediate the action of FK506 and
rapamycin, although they do not appear to be essential for
viability (Heitman et al., 1991; Dolinski et al., 1997). Although
the enzymatic activity of PPIases is associated with the acceleration
of protein folding (Schiene and Fischer, 2000; Schiene-Fischer
and Yu, 2001), the mechanism of action of MIPs during host cell
invasion remains to be elucidated. In particular, the biological
target for the rotamase activity of MIPs has not been identified.
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Here we report the three-dimensional crystal structure of the
MIP protein from T. cruzi at 1.7 Å resolution. This resolution
allows a detailed view of the molecule and, in particular, of the
active site, opening the possibility of designing new specific
inhibitors that might impair trypanosomal invasion.
RESULTS AND DISCUSSION
Overall structure and active site
TcMIP is a 167-residue monomeric protein with a molecular
mass of 18.8 kDa and overall dimensions 57 × 40 × 25 Å3. It
consists of a central catalytic rotamase-like core surrounded by
additional helical secondary structure elements (Figure 1A). The
core is composed of a six-stranded anti-parallel β-sheet and a
short α-helix (α2) (Figure 1B). The β-sheet has 1–2–5–6–3–4
topology and wraps, with a right-handed twist, around helix α2.
Strand β4 is split into two segments (termed β4a and β4b),
separated by a large seven-residue bulge that includes an α-helical
turn. This arrangement resembles a closed left hand, with the
fingers represented by the β-strands, wrapping around the
thumb, mimicked by helix α2.
Following the left-hand analogy, a long α-helix (α1) is located
on top of the fingers, and exposed to the exterior. α-Helix α1
precedes the outermost strand β1, covering most of loop β5–β6
and part of β-strands β1, β2 and β5 (Figure 1B). The N-terminus
of helix α1 protrudes from the protein core, with which its
C-terminal half makes exclusively hydrophobic contacts, over
an area of ∼600 Å2. The second largest helix of TcMIP (α3) is
located at the C-terminus of the protein and, unlike helix α1, it
has a net negative charge at its surface. Helix α3 is stabilized by
salt bridges between Arg72 (of strand β2) and Glu190, and
between Arg131 (of loop α2–β6) and Asp183, in addition to
hydrophobic contacts with the core of the protein. Because this
helix is located at the face of the protein core opposite to the
active site, loop β6–α3 crosses over loop β2–β3, with which
it forms three main-chain to main-chain hydrogen bonds
(Figure 1B).
The active site of TcMIP is located in the palm of the hand and
is a deep hydrophobic pocket formed by residues from β-strands
β3, β4 and β6, from α-helix α2, and from loop β5–β6 (Figure 2).
The side chains of residues Tyr92, Phe102, Asp103, Arg108,
Phe114, Val119, Ile120, Tyr146, Ile155 and Phe163 form the
walls of this pocket, with the side chain of Trp123 at its bottom.
The side chains of residues Tyr92, Asp103 and Arg108 form a
hydrogen-bonded cluster.
Comparison with FKBPs and L. pneumophila MIP
The central core of TcMIP is structurally similar to that of FKBPs
(Michnick et al., 1991; Moore et al., 1991; Van Duyne et al.,
1991, 1993; Wilson et al., 1995; Choi et al., 1996; Burkhard et
al., 2000; Deivanayagam et al., 2000). FKBPs are functionally
similar to other PPIases (e.g. cyclosporins and parvulins), from
which they diverge at the primary and tertiary structure levels
(Kallen et al., 1991; Wilson et al., 1995; Ranganathan et al.,
1997; Deivanayagam et al., 2000). Superposition of TcMIP with
human FKBP12 (Van Duyne et al., 1993) reveals 104 topologically
equivalent Cα atoms, with a root mean square deviation
(r.m.s.d.) of 1.2 Å (Figure 2A). However, in TcMIP the central
β-sheet is extended by one extra strand (β1), as described for
rabbit FKBP59 (Craescu et al., 1996). The greatest deviations
between the rotamase core of TcMIP and FKBP12 occur in loop
regions. In TcMIP, loop β4b–α2 is two residues shorter than in
human FKBP12, which makes it more compact and allows loop
β2–β3 to move in closer, packing between loop β4b–α2 and the
segment connecting strand β7 and helix α3. Furthermore, FKBPs
lack the surface helices α1 and α3.
The sequence identity of TcMIP with bacterial MIPs ranges
from 26 to 38%, with considerable homology in the rotamase
core region, while the N- and C-terminal segments differ more
(Figure 1A). The first structure of a protein of this family, the
macrophage infectivity potentiator protein from L. pneumophila
(LpMIP), has been reported recently (Riboldi-Tunnicliffe et al.,
2001). A structural comparison between TcMIP and LpMIP
shows a common fold for the rotamase core (Figure 2A). The two
structures have 128 topologically equivalent Cα atoms, with an
r.m.s.d. of 1.0 Å. As with TcMIP, the central β-sheet of LpMIP is
extended by one extra strand (β1). In addition, loops β4b–α2
and β2–β3 of LpMIP closely resemble those from TcMIP, rather
than those of FKBP12.
The structure of the binding pocket of TcMIP is very similar to
that of human FKBP12, except for Phe114, whose side chain
occupies the position of that of Phe46 in FKBP12 (Figure 2B),
replaced in TcMIP by the less bulky Thr112. The void created
by the movement of Phe114 is partially filled by the side chain
of Leu127, replacing Val63 of FKBP12. The distinct rotamer
observed for Phe114 in TcMIP, when compared with FKBP12,
is also observed in the active site of LpMIP due to the presence of
an alanine residue in the position occupied by Thr112 in TcMIP.
The active sites of TcMIP and LpMIP also differ in the H-bonded
cluster formed by Tyr92, Asp103 and Arg108, conserved in
FKBP12 (Van Duyne et al., 1991, 1993). In LpMIP, Arg108 is
replaced by a threonine, thus disrupting the H-bond network.
Helix α1 is longer in LpMIP and is significantly bent along the
surface of the protein core, being fixed to the body of the protein
by three distinct contacts: a water-mediated H-bond between
Asn84 O and Thr199 N, and two main-chain to side chain
bonds between Asn84 Nδ2 and Pro196 O, and Ala81 O and
Asn197 Nδ2. In TcMIP, Pro160 replaces Thr199 of LpMIP, thus
making the first of these contacts impossible. The side chains of
Asn84 and Asn197 in LpMIP are replaced in TcMIP by Arg44
and Tyr158, respectively, which no longer form H-bonds with
main-chain atoms. At the N-terminus of LpMIP, a not very well
defined (with substantially above-average temperature factors)
and rather flexible helix bundle domain is involved in the
dimerization of the bacterial protein, being absent from the mono-
meric TcMIP. On the other hand, the C-terminal helix of TcMIP
(α3) constitutes a structural element that is unique among
MIP-like proteins and rotamases of known structure.
Specific inhibitors
The detailed structural model of TcMIP allows a better under-
standing of its active-site particularities and raises the possibility
of developing novel non-immunosuppressant specific inhibitors
of the enzyme. These are valuable research tools for identifying
its physiological targets and the infective pathway used by
T. cruzi; they may also provide novel and promising therapeutic
alternatives.
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In the absence of a complex of TcMIP with inhibitors, a
superposition with FKBP12 in its complexes with the immuno-
suppressants rapamycin [Protein Data Bank (PDB) code 1c9h;
Deivanayagam et al., 2000)] and FK506 (PDB 1bkf; Itoh and
Navia, 1995) allows us to analyze the structural determinants of
rotamase inhibition (Van Duyne et al., 1993), which can be
extrapolated to our model. Both inhibitors are bound in the
hydrophobic active-site cavity of FKBP12 between an α-helix
and the interior wall of the β-sheet. The common path runs from
approximately carbon atom C16 (rapamycin numbering; see
Figure 2B) to C31 of the macrolide rings. It includes the deeply
penetrating pipecolinyl ring (atoms C2–N7; label A in
Figure 2B), attached to the N7–C8 bond, which mimicks the
peptide bond proposed to undergo cis–trans isomerization in
Fig. 1. Structure of TcMIP. (A) Amino acid sequence alignment of TcMIP (SWISSPROT entry MIP_TRYCR) with bacterial MIPs from L. pneumophila
(SWISSPROT entry MIP_LEGPN), Vibrio cholerae (SWISSPROT entry Q9KP11) and C. trachomatis (SWISSPROT entry MIP_CHLTR), with human FKBP12
(SWISSPROT entry FKB1_HUMAN) and FKBP-like protein from E. coli (SWISSPROT entry FKBB_ECOLI). Residues conserved in all sequences are
highlighted in green, those identical to TcMIP in yellow. Signal peptide regions have been omitted. Residues forming the hydrophobic active-site pocket are
indicated by blue triangles. The numbering and the secondary structure elements of TcMIP are displayed above the alignment. α-Helices are shown in red, β-strands
in green. (B) Overall structure of TcMIP, with the secondary structure elements shown in red (α-helices) and green (β-strands). The side chains of important
residues in the active site of the enzyme are depicted as ball-and-stick models, with carbon atoms in yellow, oxygens in red and nitrogens in blue.
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a proline-containing substrate in FKBPs and rotamases (Fischer
et al., 1993; Orozco et al., 1993), the substituted cyclohexyl
moiety attached to main-chain C34 (B in Figure 2B) and the
oxacyclohexane group (C10–C14, O5; C in Figure 2B). A detailed
inspection of the active-site binding cleft of TcMIP reveals
essentially the same features as observed for the immunophilin, in
good agreement with the inhibition of TcMIP by FK506 in vitro.
Protein residues taking part in immunosuppressor binding are
equivalent in both enzymes, with the exception of two regions
(Figure 2B), which could enable one to design potential drug
candidates with a distinct selectivity profile, able to target TcMIP
rather than immunophilins. Those regions include the upper rim
of the cleft, Gly151-Gly152-Gly153-Met154 of TcMIP (Val/His87-
Pro88-Gly89-Ile90 in the FKBP12s studied, see Figure 2B) and
the segment forming the cleft base, Thr112-Thr113-Phe114-Arg115-
Pro116-Asn117-Glu118 (Phe46-Lys47-Phe48-Met/Arg49-Leu/Ile50-
Gly51-Lys52-Gln53-Glu54 in FKBP12s, two residue insertion).
Model building indicates that the former could allow for a large
hydrophobic group, i.e. a benzyl group, attached to carbon
atom C43 (rapamycin numbering), to reside on a hydrophobic
pillow made up by the side chains of Tyr146 and Ile155 of
TcMIP and, on the other hand, leading to steric clashes in
FKBP12 with Val87 and Ile90. The second region affects mainly
the anchoring of the pipecolinyl ring A and the attached oxacy-
clohexane moiety C (Figure 2B). Accordingly, an ethyl group
attached to rapamycin C44 would be capable of constructive
interactions with TcMIP Thr112 and Phe114, but probably inter-
fere with Phe46 in FKBP.
Hypothetical mechanism of action
Two alternative mechanisms of action can be proposed for
TcMIP. In the first, only binding of TcMIP to a protein target—
but not its rotamase activity—is necessary to trigger a signal in
the host cell, leading to enhanced invasion. The rotamase
inhibitor FK506 and its non-immunosuppressant derivative
L-685,818, which exhibits antifungal activity (Odom et al.,
1997), inhibit TcMIP infectivity (Moro et al., 1995) and block its
active site (Figure 2B). Thus, inhibitor binding may hinder the
interaction of TcMIP with its physiological target. Alternatively,
Fig. 2. TcMIP is homologous to other FK506-binding proteins. (A) Stereo view of the Cα trace of TcMIP (red) superimposed with those of L. pneumophila MIP
(blue; PDB code 1FD9) and human FKBP12 (yellow; PDB code 1FKJ). (B) Stereo close-up view of the active site of TcMIP (atom colour code) superimposed
with that of the human FKBP12–FK506 complex (green; PDB code 1bkf) and the FKBP12–rapamycin complex (blue; PDB code 1c9h). Some key residues and
regions of the immunosuppressors discussed in the text are labeled.
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the experimentally demonstrated rotamase activity of TcMIP
(Moro et al., 1995) could contribute to its action mechanism.
The three-dimensional structure of TcMIP reported here shows a
FKBP-like core fold, with conserved structure of the active site.
Such a stringent three-dimensional conservation is probably
driven by maintenance of enzymatic activity.
Pre-treatment of the host with recombinant TcMIP increases
T. cruzi infectivity, indicating that its target resides in the host
cell (Moro et al., 1995). Signaling through transforming growth
factor-β receptor (TGFβR) is required for trypanosomal invasion
of epithelial cells (Ming et al., 1995), making it a candidate
target for TcMIP. However, attempts to induce the expression of
a reporter gene under the control of a TGFβ-inducible promoter
failed (A. Gonzalez et al., unpublished results), arguing against
TGFβR being the natural target of TcMIP.
FKBP12 has been found tightly associated with calcium
release channels from both the sarcoplasmic and the endo-
plasmic reticulum (Collins, 1991; Jayaraman et al., 1992;
Cameron et al., 1995). By analogy, TcMIP could bind to trans-
membrane channels of the host cell, modulating intracellular
calcium levels. Mobilization of Ca2+ both in the parasite and
the target cell during invasion has been reported, while depletion
of the intracellular Ca2+ concentration hinders invasion (Moreno et
al., 1994; Tardieux et al., 1994; Yakubu et al., 1994; Dorta et al.,
1995; Rodriguez et al., 1995; Wilkowsky et al., 1996).
A T. cruzi infectivity assay was performed in order to compare
the effectiveness of TcMIP and LpMIP. As shown in Table I,
while 450 nM GST–TcMIP causes a 4-fold increase in the
number of internalized parasites (see Methods), a similar
concentration of GST–LpMIP causes a 48% increase over
controls. Since LpMIP acts as a dimer, its actual concentration in
the assay is 225 nM. At 250 nM, TcMIP roughly doubles the
number of internalized parasites. These results indicate that
LpMIP can effectively substitute for TcMIP and, thus, it is reason-
able to believe that, in the assay, they interact in a similar way
on a common protein target. In structural terms, both proteins share
the conserved rotamase core, and have an additional β-strand in the
central β-sheet and an exposed N-terminal α-helix. It is tempting to
speculate that helix α1 is a recognition or specificity element in
the interaction with the host target protein. The differences in the
oligomeric state and between the N-terminal portions of the two
proteins could account for the differences observed in their
invasion-enhancing action.
METHODS
Protein preparation and LpMIP invasion assay. Recombinant
TcMIP was produced by scaling up the methods described
elsewhere (Moro et al., 1995). After GST removal, TcMIP was
further purified by ion-exchange chromatography (MonoQ).
The material used for crystallization consists of amino acids
30–196 of TcMIP preceded by an extra glycine residue from
the thrombin recognition sequence. The computer-predicted
leader peptide cleavage site is located between amino acids
29 and 30.
The coding region of the LpMIP gene, without the leader
peptide, was amplified by PCR from L. pneumophila strain
Philadelphia 1 DNA using specific primers based on the published
sequence (Fischer et al., 1992). A fusion protein with GST was
expressed in Escherichia coli and purified by standard procedures.
Cleavage of the fusion protein with thrombin to remove GST
resulted in precipitation of LpMIP. Nonetheless, the fusion
protein shows rotamase activity levels in good agreement with
those published for native LpMIP (Fischer et al., 1992). Further-
more, GST–TcMIP presents slightly higher rotamase activity than
TcMIP alone (our unpublished results). An invasion assay was
carried out as described previously (Moro et al., 1995) to deter-
mine whether GST–LpMIP can functionally replace GST–TcMIP.
Crystallization and data collection. Purified recombinant
protein was dialyzed against 5 mM Tris–HCl pH 7.5, 1 mM
PMSF and stored at 4°C. Protein crystals of approximate dimen-
sions 0.9 × 0.2 × 0.3 mm3 appeared spontaneously in this solu-
tion within 4–6 weeks. The crystals were harvested in 5 mM
Tris–HCl pH 7.5, 10% PEG 6000 and flash frozen in liquid
nitrogen prior to data collection. Diffraction data up to 1.7 Å
were collected from a single crystal, kept at 100 K, at EMBL
beamline BW7B (DESY, Hamburg). The crystals belong to space
group P21 with cell dimensions a = 46.0 Å, b = 34.6 Å,
c = 50.4 Å and β = 91.6°, and contain one TcMIP molecule per
asymmetric unit (solvent content 41.7%). Data were processed
with MOSFLM (Leslie, 1999) and scaled with SCALA (CCP4,
1994). Table II summarizes data collection and processing
statistics.
Structure solution and refinement. The structure was solved by
molecular replacement with AMoRe (Navaza, 1994), using as a
search model the coordinates of residues 88–212 of Lp MIP (PDB
code 1FD9), with all non-identical non-glycine residues truncated
to alanine. A clear solution was obtained using data in the 15–3.5
Å range, with a correlation coefficient of 19.4 and an Rfactor of
54.2% (second highest solution: correlation coefficient of 11.4
and an Rfactor of 56.0%). Cycles of positional and temperature
factor refinement with CNS v.1.0 (Brünger et al., 1998), applying
bulk solvent and global anisotropic B-factor corrections, alter-
nating with manual model building on a graphic workstation
using Turbo-FRODO (Roussel and Cambillau, 1989), allowed us
to improve the model and to trace the additional structural
elements not included in the rotamase core. Model refinement
was completed with SHELX97-2 (Sheldrick and Schneider,
1997), using isotropic thermal parameters. The final model,
obtained after a refinement run with all the data, without Rfree
calculation, comprises residues 33–192 of TcMIP (numbering
according to the deposited amino acid sequence; SWISSPROT
entry MIP_TRYCR) and 271 solvent molecules. All residues are
found in allowed regions of the Ramachandran plot, as verified with
PROCHECK within (CCP4, 1994), which confirms the high quality
of the final model. The three N-terminal residues as well as the
C-terminal four amino acids of mature TcMIP are not well defined
Table I. LpMIP can substitute for TcMIP in T. cruzi infectivity assay
Added component No. of internalized parasites/200 cells
Ringer’s solution 140 ± 5
450 nM GST 113 ± 8
450 nM GST–LpMIP 192 ± 3
450 nM GST–TcMIP 432 ± 8
250 nM GST–TcMIP 278 ± 13
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in the electron density maps and were not included in the present
model. Table III presents a summary of the refinement statistics.
Miscellaneous. Structural homology searches were performed
with the DALI server (http://www.ebi.ac.uk/dali/). Figure 1A was
produced with ALSCRIPT (Barton, 1993), and Figures 1B, 2A
and B with SETOR (Evans, 1990). The coordinates have been
deposited with the PDB (accession code 1JVW).
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